Clinical Trials Logo

Hepatic Function clinical trials

View clinical trials related to Hepatic Function.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02421042 Completed - Hepatic Impairment Clinical Trials

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Start date: June 2011
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, non-randomized, single-dose, sequential-cohort study in subjects with varying degrees of hepatic impairment, classified according to the Child-Pugh system, who will be matched with normal healthy subjects as controls.

NCT ID: NCT00600912 Completed - Clinical trials for Inflammatory Response

Influence of of a Lipid Emulsion on Inflammatory Response and Hepatic Function

Start date: December 2006
Phase: Phase 4
Study type: Interventional

Lipid emulsions are an essential part of parenteral nutrition, both as a part of energy supply, and as a source of essential fatty acids. It has been shown that the fatty acid composition of cell membranes is influenced by the fatty acid profile of dietary lipids, and may therefore be responsible for modulation of immune response. The aim of this study was to assess the effects of a new lipid emulsion based ob soybean oil, medium-chain triglycerides, olive oil and fish oil compared with a lipid emulsion based on olive and soybean oil on the inflammatory response and hepatic function in postoperative intensive care unit (ICU) patients.

NCT ID: NCT00586118 Completed - Renal Function Clinical Trials

Inhalative Sedation in ICU With Sevoflurane Via Anaesthetic Conserving Device Compared to Propofol

Start date: December 2006
Phase: N/A
Study type: Observational

The evaluation of the presented study will work on the practicability of inhalative sedation on the ICU, potential benefits and limitations of the ACD system in a postoperative sedated patient population in comparison to a standard intravenous sedation regimen with propofol, and focus on renal and hepatic function, cardioprotection and pharmacoeconomics